Related Experiment Video

Updated: Dec 25, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.2K

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

Luca Cantini1,2,3, Raffit Hassan4, Daniel H Sterman5

  • 1Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.

Frontiers in Oncology
|April 1, 2020
PubMed

Insights

Malignant pleural mesothelioma (MPM) remains a challenging cancer. Emerging immunotherapies show promise, but careful clinical trial design and patient selection are crucial for future treatment advancements.

Area of Science:

  • Oncology
  • Immunology
  • Thoracic Surgery

Background:

  • Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer with poor prognosis.
  • Recent advances in understanding MPM pathobiology have spurred the development of novel therapeutic strategies.

Purpose of the Study:

  • To review promising emerging therapies for MPM treatment.
  • To discuss the biological rationale, clinical trial design, and patient selection for these novel treatments.

Main Methods:

  • Literature review of recent studies on MPM therapies.
  • Analysis of biological underpinnings of novel treatment approaches.
  • Evaluation of clinical trial data and patient stratification strategies.

Main Results:

  • Immunotherapy is a key area of investigation for MPM.
  • Phase II successes in MPM have not always translated to Phase III trials.
  • Optimizing clinical trial design and patient selection is critical.

Conclusions:

  • Emerging therapies, particularly immunotherapy, offer hope for MPM treatment.
  • Further research is needed to overcome challenges in clinical trial validation.
  • Personalized approaches are essential for improving outcomes in MPM.
Keywords:
Malignant mesotheliomaanti-angiogeniccheckpoint inhibitorsdendritic cell therapyimmunotherapymesothelintargeted therapytumor-treating fields

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.2K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.6K

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
511
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
523
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K